Atlanta, GA, United States of America

John Wiseman



 

Average Co-Inventor Count = 5.3

ph-index = 4

Forward Citations = 37(Granted Patents)


Company Filing History:


Years Active: 2012-2018

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: The Innovations of John Wiseman

Introduction

John Wiseman is a notable inventor based in Atlanta, GA, who has made significant contributions to the field of pharmaceutical sciences. With a total of five patents to his name, Wiseman's work primarily focuses on chemokine CXCR4 receptor modulators, which have important implications for managing viral infections and cancer.

Latest Patents

Wiseman's latest patents include innovative chemokine CXCR4 receptor modulators and their related uses. The disclosures detail pharmaceutical compositions that comprise compounds or their pharmaceutically acceptable salts or prodrugs. These compositions are particularly aimed at managing CXCR4-related conditions, which typically involve the prevention or treatment of viral infections such as HIV, as well as cancer management.

Career Highlights

Throughout his career, John Wiseman has worked with esteemed organizations such as Emory University and Altiris Therapeutics, Inc. His experience in these institutions has allowed him to develop and refine his innovative ideas, contributing to advancements in medical treatments.

Collaborations

Wiseman has collaborated with notable colleagues, including Michael G Natchus and Lawrence J Wilson. These partnerships have further enhanced his research and development efforts in the pharmaceutical field.

Conclusion

John Wiseman's contributions to the field of pharmaceutical sciences through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in the treatment of serious health conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…